Please assess the completion status of the following clinical trial:

Trial Title: NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Provision of signed written informed consent.~2. Original diagnosis and/or histological confirmation of high-grade serous, high-grade endometrioid, undifferentiated/unclassifiable epithelial ovarian, fallopian tube or primary peritoneal cancer.~3. Time from the last line of platinum-based chemotherapy of less than 6 months.~4. Received at least 3 prior chemotherapy-containing regimens.~5. Age ≥18 years.~6. Ability to comply with protocol requirements.~7. Patients are not of childbearing potential or they must agree to use a physical method of contraception.~Exclusion Criteria:~1. Disease that progressed while receiving initial line of platinum-based chemotherapy.~2. Received fewer than 3 prior chemotherapy-containing regimens.~3. Prior therapy with single-agent gemcitabine.~4. Prior history of hypersensitivity to gemcitabine.~5. Prior chemotherapy, radiation (other than short cycle of radiation to reduce bone pain), treatment with a VEGF inhibitor, PARP inhibitor or immunotherapy within 21 days of first receipt of study drug. Hormone therapy within 14 days of first receipt of study drug.~6. Residual side effects from chemotherapy or radiation, which have not gotten better except for nerve pain or tingling or hair loss.~7. Patients who have a history of another type of cancer diagnosed within the past 5 years, with the exception of adequately treated non-melanoma skin cancer curatively treated cervical cancer or ductal carcinoma in situ (DCIS) of the breast.~8. Presence of an serious illness, uncontrolled illness, or active infection requiring IV antibiotics.~9. Presence of any serious illnesses, serious medical conditions, serious medical history, active bacterial or viral infections including hepatitis B or C, or known to be HIV positive.~10. Currently pregnant, lactating or breastfeeding.~11. History of blocked intestines because of ovarian cancer, unless fully resolved.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): NUC-1031 500 mg/m2 administered on Days 1, 8, and 15 of 28-day cycles
- Arm B (Type: EXPERIMENTAL): NUC-1031 750 mg/m2 administered on Days 1, 8, and 15 of 28-day cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).